Treatment failure in pneumonia: Impact of antibiotic treatment and cost analysis

European Respiratory Journal

Volumn 39, Issue 3, 2012, Pages 611-618

  Ott, S R ^a   Hauptmeier, B M ^c   Ernen, C ^d   Lepper, P M ^e   Nuesch E ^a,b   Pletz, M W ^f   Hecht, J ^g   Welte, T ^h   Bauer, T T ^g  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d Institute of Empirical Health Economics   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f JENA UNIVERSITY HOSPITAL   (Germany)

^g LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^h HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

Community acquired pneumonia; Cost effectiveness; Moxifloxacin; Treatment failure

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; LINCOSAMIDE; MACROLIDE; MOXIFLOXACIN; NITROIMIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL COST; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HUMANS; LENGTH OF STAY; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA; QUINOLINES; TREATMENT FAILURE;

EID: 84860348367     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00098411     Document Type: Article

References (33)

1. Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-1069.
2. Gulsvic A. Major respiratory diseases. In: Loddenkemper GG, Gibson GJ, Sibille R, eds. European Lung White Book. Sheffield, European Respiratory Society, 2003; pp. 55-64.
3. Menéndez R, Torres A, Zalacaín R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960-965.
4. Genne D, Kaiser L, Kinge TN, et al. Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials. Clin Microbiol Infect 2003; 9: 949-954. (Pubitemid 37236162)
5. Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162: 154-160. (Pubitemid 30469813)
6. Genné D, Sommer R, Kaiser L, et al. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25: 159-166.
7. Reyes S, Martinez R, Vallés JM, et al. Determinants of hospital costs in community-acquired pneumonia. Eur Respir J 2008; 31: 1061-1067.
8. Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005; 128: 2238-2246. (Pubitemid 41507565)
9. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283: 749-755. (Pubitemid 30084614)
10. Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003; 124: 526-535. (Pubitemid 37000129)
11. Menéndez R, Torres A, Rodríguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39: 1783-1790.
12. Bauer TT, Ewig S, Marre R, et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006; 260: 93-101. (Pubitemid 43894075)
13. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250. (Pubitemid 27044625)
14. Critical Assesment of Economic Evaluation. In: Drummond MF, Sculpher MJ, Torrance GW, et al, eds. Methods for the Economic Evaluation of Health Care Programs. Oxford, Oxford University Press, 1987; pp. 18-32.
15. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997; 10: 1530-1534. (Pubitemid 27311067)
16. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000; 109: 378-385.
17. Colice GL, Morley MA, Asche C, et al. Treatment costs of community-acquired pneumonia in an employed population. Chest 2004; 125: 2140-2145. (Pubitemid 38788182)
18. Musher DM, Rueda AM, Kaka AS, et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007; 45: 158-165. (Pubitemid 47041005)
19. Aliberti S, Amir A, Peyrani P, et al. Incidence, etiology, timing and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest 2008; 134: 955-962.
20. Tessmer A, Welte T, Martus P, et al. Impact of intravenous β-lactam/macrolide versus b-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother 2009; 63: 1025-1033.
21. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003; 3: 359-371. (Pubitemid 36718015)
22. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005; 18: 125-131. (Pubitemid 40380211)
23. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42: 410-425. (Pubitemid 26379929)
24. Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999; 44: 835-838.
25. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: 1452-1457. (Pubitemid 28228202)
26. Montravers P, Fagon JY, Chastre J, et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 1993; 147: 38-44. (Pubitemid 23025912)
27. Ortqvist A, Kalin M, Lejdeborn L, et al. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia. Chest 1990; 97: 576-582. (Pubitemid 20095572)
28. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72. (Pubitemid 46290553)
29. Menéndez R, Torres A, Zalacaín R, et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005; 172: 757-762.
30. Menendez R, Reyes S, Martinez R, et al. Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia. Eur Respir J 2007; 29: 751-756. (Pubitemid 46554626)
31. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180. (Pubitemid 41829947)
32. Höffken G, Lorenz J, Kern W, et al. Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen tiefen Atemwegsinfektionen sowie ambulant erworbener Pneumonie - update 2009 [Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany]. Pneumologie 2009; 63: e1-68.
33. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: Suppl. 3, iii1-iii55.